Diabetic macular edema (DME)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) The patient is informed of this study and has signed an informed consent form, willing to execute it in accordance with the requirements of the clinical trial protocol; (2) OCTA examination showed macular edema, with a thickness of = 300 within a range of 1 mm in diameter in the central area of the macula measured µ m. Record blood flow density; (3) Treatment without macular grid like photocoagulation, intravitreal injection of triamcinolone acetonide, intravitreal injection of anti VEGF drugs, etc; (4) Age>18 years old.
Exclusion criteria
Exclusion criteria: (1) Refractive interstitial opacity affects fundus observers; (2) Patients with combined eye diseases such as glaucoma, uveitis, and optic nerve disease; (3) Poor overall condition, combined with severe cardiovascular, cerebrovascular, liver, and hematopoietic system diseases, as well as severe life-threatening primary diseases and psychiatric patients; (4) Patients with unstable myocardial infarction, cerebral infarction, and other contraindications for intravitreal anti VEFG injection; (5) Participants in clinical trials of other drugs; (6) Individuals who are unable to cooperate in completing various examinations due to age, illness, or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| General patient information;Best Corrected Visual Acuity (BCVA);Central Macular Thickness (CMT);DRSS score;Biochemical Indicators;Area of FAZ;Perimeter of FAZ;Complication;IL-6, IL-8, IL-10, VEGF, PFGF in anterior aqueous humor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intra-Ocular pressure (IOP);deep blood flow density;superficial blood flow density; | — |
Countries
China
Contacts
Inner Mongolia Chaoju Eye Hospital